Arrowhead Reports Fiscal 2010 Third Quarter
August 12, 2010 04:03 PM Eastern Daylight Time
PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research Corporation (NASDAQ:ARWR)
today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.
“In the third quarter, we continued to advance our late-stage subsidiaries and build on the momentum we began early
in the calendar year,” said Christopher Anzalone, Arrowhead’s CEO. “In-line with our expectations, Calando’s first-
in-class Phase I interim results continue to generate interface opportunities with potential partners. Also, Unidym
secured additional joint development agreements with two large partners. With the completion of our successful $8.7
million financing, we have the capital to support the disciplined implementation of Calando’s and Unidym’s strategies
and to invest in future initiatives designed to accelerate growth. We have already selected, for diligence and potential
acquisition, an exciting technology that addresses the large, underserved obesity market opportunity. With these
achievements, we are making important strategic advancements to build a robust and unique portfolio of
THIRD QUARTER FISCAL 2010 AND RECENT COMPANY HIGHLIGHTS:
l Business highlights:
¡ Arrowhead secured $8.7 million in financing through a registered direct offering of stock and warrants.
¡ Arrowhead rejoined the Russell Microcap Index.
¡ Presented interim data from majority-owned subsidiary Calando Pharmaceuticals, Inc.’s Phase I human
trial of its anti-cancer siRNA therapeutic, CALAA-01, at the American Society for Clinical Oncology
Annual (ASCO) Meeting.
¡ Unidym entered joint development agreements with Tokyo Electron and Guardian Glass, two global
companies developing products for the display industry.
¡ Arrowhead signed an option agreement with The University of Texas MD Anderson Cancer Center to
negotiate a license in a defined field to a class of compounds tha